Australia
GlyTherix Ltd. is an Australian immuno-oncology company founded in 2017 that specializes in highly targeted cancer therapy and imaging. The company is focused on developing Miltuximab® for the targeted treatment of several solid tumors, including prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian, and brain cancers. At the core of their technology is a protein known as Glypican-1 (GPC-1), which occurs in many solid tumors but is not present in healthy tissue.
GlyTherix has a strong proprietary and Intellectual Property position covering both Miltuximab®, its anti-GPC-1 antibody, and the antigen itself, GPC-1, providing robust and long-term protection for the commercialization of important new treatments. The company has completed a 'First-in-Human' trial of 12 patients using Miltuximab® with no drug-related adverse events observed, demonstrating the safety and potential efficacy of their therapeutic approach.
GlyTherix is actively seeking partnerships or collaborations with larger pharmaceutical partners to advance the development and commercialization of their innovative cancer therapies. With its focus on addressing unmet medical needs in cancer treatment and the promising results of its initial trials, GlyTherix presents an intriguing opportunity for potential investors looking to support groundbreaking advancements in cancer therapy.
